Exicure Announces Phase 1b Poster Presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meet...
October 19 2020 - 7:00AM
Business Wire
Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and
immunotherapeutic drugs utilizing proprietary spherical nucleic
acid (SNA™) technology, announced an upcoming poster presentation
for its intratumoral product candidate, cavrotolimod (AST-008), at
the 35th Anniversary Annual Meeting of the Society for
Immunotherapy of Cancer (SITC), to be held virtually from November
9-14, 2020. Cavrotolimod, the company’s SNA-enabled TLR9 agonist,
is being developed for the treatment of solid tumors, in
combination with anti-programmed cell death 1 (PD-1) therapy.
Details are as follows:
Title: Safety and preliminary
efficacy of intratumoral cavrotolimod (AST-008), a spherical
nucleic acid TLR9 agonist, in combination with pembrolizumab in
patients with advanced solid tumors
Authors: Steven J. O’Day, Cesar A.
Perez, Trisha M. Wise-Draper, Glenn J. Hanna, Shailender Bhatia,
Ciara M. Kelly, Theresa M. Medina, Douglas E. Laux, Adil Daud,
Sunandana Chandra, Montaser Shaheen, Ling Gao, Melissa A. Burgess,
Leonel Hernandez-Aya, Emil M. deGoma, Weston L. Daniel, Douglas E.
Feltner, Laurel Sindelar, Robert E. Michel, Alice S. Bexon, Martin
Bexon, and Mohammed M. Milhem
Poster/Abstract Number: 423
The abstract and poster can be accessed on the SITC
website once the conference begins on Monday, November 9th at
8:00 a.m. EST. The poster will also be made available on the
Exicure website.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for neurology, immuno-oncology,
inflammatory diseases and other genetic disorders based on our
proprietary spherical nucleic acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN, an
SNA–based therapeutic candidate, for the treatment of Friedreich’s
ataxia (FA). Exicure's therapeutic candidate cavrotolimod is in a
Phase 1b/2 clinical trial in patients with advanced solid tumors.
Exicure is based in Chicago, IL and in Cambridge, MA.
For more information, visit Exicure’s website at
www.exicuretx.com.
Exicure Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements in this press release other than statements of
historical fact could be deemed forward looking including, but not
limited to, statements regarding the company’s ongoing Phase 1b/2
clinical trial of cavrotolimod (AST-008) including the design,
clinical development, therapeutic potential and clinical results
and expectations as to the reporting of data;. The forward-looking
statements in this press release speak only as of the date of this
press release, and the company undertakes no obligation to update
these forward-looking statements. Forward-looking statements are
based on management’s current beliefs and assumptions that are
subject to risks and uncertainties and are not guarantees of future
performance. Actual results could differ materially from those
contained in any forward-looking statement as a result of various
factors, including, without limitation: the risks that the ongoing
COVID-19 pandemic may disrupt the company’s business and/or the
global healthcare system more severely than it has to date or more
severely than anticipated, which may have the effect of impacting
or delaying the company’s ongoing Phase 1b/2 clinical trial;
unexpected costs, charges or expenses that reduce the company’s
capital resources; the company’s preclinical or clinical programs
do not advance or result in approved products on a timely or cost
effective basis or at all; the results of early clinical trials are
not always being predictive of future results; the cost, timing and
results of clinical trials; that many drug candidates do not become
approved drugs on a timely or cost effective basis or at all; the
ability to enroll patients in clinical trials; possible safety and
efficacy concerns; regulatory developments; and the ability of the
company to protect its intellectual property rights. For a
discussion of other risks and uncertainties, and other important
factors, any of which could cause the company’s actual results to
differ from those contained in the forward-looking statements, see
the section titled “Risk Factors” in the company’s Annual Report on
Form 10-K for the year ended December 31, 2019, as updated by the
company’s subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and the company undertakes no duty to update this
information, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201019005203/en/
For Media: Karen Sharma MacDougall 781-235-3060
ksharma@macbiocom.com
For Investors: Thomas Hoffmann Solebury Trout
+1-646-378-2931 thoffmann@troutgroup.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024